Table 1.
Demographic Data of Participants Diagnosed with COVID-19 (N = 52).
| Variables | a-taVNS (N = 26) | s-taVNS (N = 26) |
|---|---|---|
| Participants | ||
| Sex, male n (%) | 16 (61%) | 10 (38%) |
| Age (years), mean (SD) | 53 (17) | 57 (16) |
| Weight (kg), mean (SD) | 83 (13) | 86 (17) |
| Height (m), mean (SD) | 1.67 (7) | 1.66 (7) |
| BMI (Kg/m2), mean (SD) | 30 (4) | 31 (6) |
| SBP (mmHg), mean (SD) | 124 (17) | 126 (29) |
| DBP (mmHg), mean (SD) | 78 (10) | 75 (12) |
| HR (bpm), mean (SD) | 83 (13) | 80 (16) |
| IL-6 (pg/mL), mean (SD) | 32 (28) | 43 (38) |
| IL-10 (pg/mL), mean (SD) | 10 (9) | 8 (6) |
| CRP (mg/dL), mean (SD) | 9 (7) | 11 (10) |
| Cortisol (ug/dL), mean (SD) | 21 (17) | 25 (21) |
| LF (n.u), mean (SD) | 52 (27) | 50 (31) |
| HF (n.u), mean (SD) | 48 (27) | 50 (31) |
| HF/LF ratio, mean (SD) | 3 (5) | 3 (4) |
| Anxiety, mean (SD) | 8 (3) | 5 (3) |
| Depression, mean (SD) | 5 (4) | 3 (3) |
| Onset of Symptoms (days), mean (SD) | 9 (2) | 9 (2) |
| Death (n) | 4 | 6 |
| Comorbidities | ||
| AH, n (%) | 12 (46%) | 15 (58%) |
| Diabetes mellitus, n (%) | 7 (27%) | 7 (27%) |
| Obesity, n (%) | 11 (42%) | 13 (50%) |
| COPD, n (%) | 1 (4%) | 7 (27%) |
| Smokers, n (%) | 1 (4%) | 1 (4%) |
| Vaccinated, n (%) | 21 (81%) | 15 (58%) |
| Pfizer, n (%) | ||
| 1st dose | 2 (8%) | 1 (4%) |
| 2nd dose | 1 (4%) | 0 (0%) |
| CoronaVAC, n (%) | ||
| 1st dose | 12 (46%) | 10 (38%) |
| 2nd dose | 9 (35%) | 10 (38%) |
| AstraZeneca, n (%) | ||
| 1st dose | 6 (23%) | 3 (12%) |
| 2nd dose | 4 (15%) | 2 (8%) |
| Janssen, n (%) | 1 (4%) | 1 (4%) |
Legend: Values presented in absolute frequency, mean, and standard deviation (SD). BMI (Body mass index), SBP (Systolic blood pressure), DPB (Diastolic blood pressure), HR (Heart Rate), mmHg (millimeter per mercury), IL-6 (Interleukin-6), IL-10 (Interleukin-10), CRP (C-reactive protein), LF (low frequency), HF (high frequency), LF/HF (low frequency and high frequency ratio), bpm (beat per minute), AH (arterial hypertension), COPD (chronic obstructive pulmonary disease).